Strategic Overview

EMPE develops mfloDx, a molecular test for TB and drug resistance detection.

Innovation Portfolio

mfloDx™ MDR-TB
Category: DRUG RESISTANCE Stage: Commercial

Comprehensive molecular test for multidrug-resistant TB detection including rifampicin and isoniazid resistance markers. Designed for district laboratory deployment.

Molecular Sputum

Key Milestones

mfloDx MDR-TB drug resistance test
RIF resistance: 93% sensitivity
<3 hour turnaround
District-level capability
Commercial availability